Why Liquidia Stock Was Diving This Week
It needed to post a blowout quarter instead of the good one it delivered.
Overview
Liquidia (NASDAQ: LQDA) hasn't been the healthiest healthcare stock on the exchange over the past few days. On Wednesday, the commercial-stage biotech published a quarterly earnings report that led to a pronounced sell-off; as of early Friday morning, its shares were down by 20% week to date.
In its second quarter, Liquidia's revenue totaled almost $171.7 million, far higher than the $8.8 million it posted in the same period of 2025. That sharp rise was due almost entirely to increases in sales volume of the company's lone commercialized drug, the pulmonary hypertension treatment Yutrepia, which hit the market in June of that year.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.